| Name | Title | Contact Details |
|---|
DirectRx is an independent pharmacy dedicated to providing patients with unparalleled, personalized pharmaceutical care. At DirectRx Pharmacy, the patient, physician and pharmacy form a circle of integrated services and coordinated care. There are no gaps in patient care between physician and pharmacy, because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our sense of urgency and commitment to unparalleled customer care makes DirectRx unique in the marketplace. We are large enough to provide the full range of pharmaceutical solutions and medications required to optimally treat chronic disease states, yet small enough to care that each patient stays on their prescribed regimen and receives the support they need throughout the course of their treatment. We believe in innovative ideas. Breaking traditional methods, DirectRx has an integration of care between the patient and the provider including a support system for the patient, from help with financial assistance to expert advice on how to manage the complicated drug regimens. DirectRx is accredited by NABP, ACHC, URAC and WBENC. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. As a family-owned business, the company has grown to serve more than 20 states since its inception more than two decades ago. Investments in technology help to provide clients with accurate, timely orders at competitive prices. DirectRx is led by founder and CEO Santa Zawaideh, R.Ph., who has been in private, independent practice since 1980. She is the proud recipient of the Michigan Pharmacist Association`s Governor`s Award and former two-term president of the Oakland County Pharmacy Association. Vice President of Clinical Services Amanda Berishaj, Pharm. D., daughter of Zawaideh, oversees the daily operations of DirectRx, as well as the clinical operations of patients with chronic disease states.
ApexCare is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Apicore, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Option Care is a leading provider of home and alternate treatment site infusion services. With a staff of more than 1,700 clinical experts – including specially trained infusion nurses, infusion pharmacists and registered dietitians – Option Care treats patients with a wide range of acute and chronic conditions. Comprehensive therapy management programs are offered for patients with nutrition disorders, bleeding disorders and heart failure, as well as those needing immunoglobulin (IG) therapy and anti-infective therapy. Option Care is able to provide services to 92% of the nation`s population through more than 90 infusion pharmacies and 100 alternate treatment sites across the country.